Novartis introduces Lucentis in state of the art pre-filled syringe

Main switchboard - Switzerland +41 61 324 11 11 - +41 61 324 80 01 - Monday - Friday, - 8:30 a.m. 5:00 p.m. GMT+1 US switchboard +1 862 778 21 00 - Monday - Friday, - 8:30 a.m. 5:00 p.m. EST More information Global Media Relations - Eric Althoff - Basel, Switzerland +41 61 324 7999 - eric.althoff [a] novartis (p) com More information Investor Relations - Switzerland investor.relations [a] novartis (p) com Monday - Friday, - 8:30 a.m. 5:30 p.m. GMT+1 - (Central European Time) Institutional investors Private investors Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine. Reporting side effects Novartis announces the launch in Europe of the Lucentis pre-filled syringe (PFS), which is specifically designed for intraocular injection - The Lucentis PFS can lead to improved patient treatment via a potential reduced risk of adverse events from non-sterile conditions - Retinal specialists and patients benefit from the potential for improved efficiency and dose accuracy offered by this innovation Basel, March 20, 2014 - Novartis has announced the launch of the Lucentis (ranibizumab) pre-filled syringe (PFS) in Germany, with other markets to follow throughout 2014. The Lucentis PFS, which received European approval in October 2013, is a new way of administering Lucentis that is specifically designed for intraocular injection to enhance patient safety and convenience for the treating clinician.